Literature DB >> 28808992

A Photoaffinity Labeling-Based Chemoproteomics Strategy for Unbiased Target Deconvolution of Small Molecule Drug Candidates.

Jason R Thomas1, Scott M Brittain1, Jennifer Lipps1, Luis Llamas1, Rishi K Jain1, Markus Schirle2.   

Abstract

The combination of photoaffinity labeling (PAL) and quantitative chemoproteomics enables the comprehensive, unbiased determination of protein interaction profiles to support target identification of bioactive small molecules. This approach is amenable to cells in culture and compatible with pharmacologically relevant transmembrane target classes like G-protein coupled receptors and ions channels which have been notoriously hard to access by conventional chemoproteomics approaches. Here, we describe a strategy that combines PAL probe titration and competition with excess parental compounds with the goal of enabling the identification of specific interactors as well as assessing the functional relevance of a binding event for the phenotype under investigation.

Keywords:  Chemoproteomics; G-protein coupled receptor; Isobaric mass tags; Photoaffinity labeling; Quantitative proteomics; Target identification

Mesh:

Substances:

Year:  2017        PMID: 28808992     DOI: 10.1007/978-1-4939-7201-2_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Discovery of a ZIP7 inhibitor from a Notch pathway screen.

Authors:  Erin Nolin; Sara Gans; Luis Llamas; Somnath Bandyopadhyay; Scott M Brittain; Paula Bernasconi-Elias; Kyle P Carter; Joseph J Loureiro; Jason R Thomas; Markus Schirle; Yi Yang; Ning Guo; Guglielmo Roma; Sven Schuierer; Martin Beibel; Alicia Lindeman; Frederic Sigoillot; Amy Chen; Kevin X Xie; Samuel Ho; John Reece-Hoyes; Wilhelm A Weihofen; Kayla Tyskiewicz; Dominic Hoepfner; Richard I McDonald; Nicolette Guthrie; Abhishek Dogra; Haibing Guo; Jian Shao; Jian Ding; Stephen M Canham; Geoff Boynton; Elizabeth L George; Zhao B Kang; Christophe Antczak; Jeffery A Porter; Owen Wallace; John A Tallarico; Amy E Palmer; Jeremy L Jenkins; Rishi K Jain; Simon M Bushell; Christy J Fryer
Journal:  Nat Chem Biol       Date:  2019-01-14       Impact factor: 15.040

2.  Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.

Authors:  Carl C Ward; Jordan I Kleinman; Scott M Brittain; Patrick S Lee; Clive Yik Sham Chung; Kenneth Kim; Yana Petri; Jason R Thomas; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

Review 3.  GLOBAL AND TARGETED PROFILING OF GTP-BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY.

Authors:  Ming Huang; Yinsheng Wang
Journal:  Mass Spectrom Rev       Date:  2020-06-10       Impact factor: 10.946

4.  Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function.

Authors:  Mai Luo; Jessica N Spradlin; Lydia Boike; Bingqi Tong; Scott M Brittain; Jeffrey M McKenna; John A Tallarico; Markus Schirle; Thomas J Maimone; Daniel K Nomura
Journal:  Cell Chem Biol       Date:  2021-01-28       Impact factor: 8.116

5.  How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins.

Authors:  Kojo Mensa-Wilmot
Journal:  Mol Pharmacol       Date:  2021-05-03       Impact factor: 4.054

6.  Harnessing the anti-cancer natural product nimbolide for targeted protein degradation.

Authors:  Jessica N Spradlin; Xirui Hu; Carl C Ward; Scott M Brittain; Michael D Jones; Lisha Ou; Milton To; Andrew Proudfoot; Elizabeth Ornelas; Mikias Woldegiorgis; James A Olzmann; Dirksen E Bussiere; Jason R Thomas; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Thomas J Maimone; Daniel K Nomura
Journal:  Nat Chem Biol       Date:  2019-06-17       Impact factor: 15.040

7.  Design, Synthesis, and Evaluation of a Diazirine Photoaffinity Probe for Ligand-Based Receptor Capture Targeting G Protein-Coupled Receptors.

Authors:  Frederike M Müskens; Richard J Ward; Dominik Herkt; Helmus van de Langemheen; Andrew B Tobin; Rob M J Liskamp; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2018-12-04       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.